Filing Details
- Accession Number:
- 0001104659-19-032915
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-30 21:26:10
- Reporting Period:
- 2019-05-28
- Accepted Time:
- 2019-05-30 21:26:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1761612 | Bicycle Therapeutics Plc | BCYC | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1185040 | Kate Bingham | C/O Bicycle Therapeutics Plc B900, Babraham Research Campus Cambridge X0 CB22 3AT | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2019-05-28 | 874,709 | $0.00 | 874,709 | No | 4 | C | Indirect | By SV Life Sciences Fund V, L.P. |
| Ordinary Shares | Acquisiton | 2019-05-28 | 623,196 | $0.00 | 1,497,905 | No | 4 | C | Indirect | By SV Life Sciences Fund V, L.P. |
| Ordinary Shares | Acquisiton | 2019-05-28 | 18,485 | $0.00 | 18,485 | No | 4 | C | Indirect | By SV Life Sciences Fund V Strategic Partners. L.P. |
| Ordinary Shares | Acquisiton | 2019-05-28 | 13,169 | $0.00 | 31,654 | No | 4 | C | Indirect | By SV Life Sciences Fund V Strategic Partners. L.P. |
| Ordinary Shares | Acquisiton | 2019-05-28 | 377,732 | $14.00 | 1,875,637 | No | 4 | P | Indirect | By SV Life Sciences Fund V, L.P. |
| Ordinary Shares | Acquisiton | 2019-05-28 | 7,983 | $14.00 | 39,637 | No | 4 | P | Indirect | By SV Life Sciences Fund V Strategic Partners. L.P. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By SV Life Sciences Fund V, L.P. |
| No | 4 | C | Indirect | By SV Life Sciences Fund V, L.P. |
| No | 4 | C | Indirect | By SV Life Sciences Fund V Strategic Partners. L.P. |
| No | 4 | C | Indirect | By SV Life Sciences Fund V Strategic Partners. L.P. |
| No | 4 | P | Indirect | By SV Life Sciences Fund V, L.P. |
| No | 4 | P | Indirect | By SV Life Sciences Fund V Strategic Partners. L.P. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Series A Preferred Shares | Disposition | 2019-05-28 | 874,709 | $0.00 | 874,709 | $0.00 |
| Ordinary Shares | Series B1 Preferred Shares | Disposition | 2019-05-28 | 623,196 | $0.00 | 623,196 | $0.00 |
| Ordinary Shares | Series A Preferred Shares | Disposition | 2019-05-28 | 18,485 | $0.00 | 18,485 | $0.00 |
| Ordinary Shares | Series B1 Preferred Shares | Disposition | 2019-05-28 | 13,169 | $0.00 | 13,169 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
- These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein
Billionaire Hedge Funds
